Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

HBPL Study of the Impact of the NK1 Antagonist Aprepitant

This study has been terminated.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Jennifer Plebani, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01176591
First received: August 4, 2010
Last updated: April 2, 2014
Last verified: April 2014

August 4, 2010
April 2, 2014
September 2010
September 2013   (final data collection date for primary outcome measure)
The impact acute dosing with aprepitant has on stress-induced craving for alcohol and cocaine in cocaine and alcohol-dependent individuals. [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
These effects will be measured using self reported data.
Same as current
Complete list of historical versions of study NCT01176591 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
Human Behavioral Pharmacology Laboratory (HBPL) Study of the Impact of the NK1 Antagonist Aprepitant (Emend®) on Stress-Induced Cocaine and Alcohol Craving

The proposed research will focus on investigating the determinants and consequences of CAD via measurement of physiological, behavioral and subjective effects of physiologic and psychologic stress cues in CAD volunteers in the laboratory, and through examination of the effects of the effects of Aprepitant, an NK1 antagonist, on the above effects. This study will examine the effects of the above stress cues on cocaine and alcohol craving under acute Aprepitant dosing, and under placebo conditions. The study is a within-subjects crossover design using 24 subjects.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • Cocaine
  • Alcohol Dependence
  • Drug: Aprepitant
    80 mg per session, oral administration.
  • Drug: Placebo
    Placebo, one per session, oral administration
  • Active Comparator: Physiological Stressor + Aprepitant
    Intervention: Drug: Aprepitant
  • Active Comparator: Psychological Stressor + Aprepitant
    Intervention: Drug: Aprepitant
  • Placebo Comparator: Physiological Stressor + Placebo
    Intervention: Drug: Placebo
  • Placebo Comparator: Psychological Stressor + Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
12
December 2013
September 2013   (final data collection date for primary outcome measure)

Inclusion Criteria

  1. Male or female and 18 years of age to 60
  2. The subject has used cocaine and alcohol at least once per month for at least the past year, and has used cocaine and alcohol within 30 days prior to signing consent.
  3. Live within a commutable distance of the Treatment Research Center (TRC) at the Penn/VA Center for Studies of Addiction, University of Pennsylvania. We define this to be a distance within the service area of Septa, within an hour drive, or a distance that both the patient and Principal Investigator (PI) find acceptable.
  4. Understands and signs the informed consent.

Exclusion Criteria:

  1. Meets DSM IV criteria for current dependence on any substance other than nicotine, cocaine ,alcohol or marijuana
  2. Subjects who test positive on the urine drug screen for any illicit drugs other than cocaine and marijuana during screening will be allowed a single retest. Those individuals who test positive for amphetamine during screening, given that they provide a copy of a prescription, will only be included if they can safely discontinue amphetamine use for the duration of the study. Subjects will need to provide a urine free of all illicit drugs other than cocaine and marijuana at study onset to be randomized. Subjects who test positive for any drugs other than marijuana prior to a study session will be allowed a single retest and a chance to reschedule their session. If the subject tests positive for any drug other than marijuana at the retest, their participation in the study will be terminated.
  3. Subjects who meet current or lifetime DSM-IV criteria for bipolar affective disorder, schizophrenia, or any psychotic disorder
  4. Current severe psychiatric symptoms- (e.g., psychosis, dementia, suicidal or homicidal ideation, mania or depression requiring anti-depressant therapy) as diagnosed using the SCID, the Hamilton Anxiety Rating Scale (Ham A), and Hamilton Ration Scale for Depression (HAM-D).
  5. Individuals scoring > 10 on the Hamilton Rating Scale for Depression (HAM-D).
  6. Use of any investigational medication within the past 30 days.
  7. Concomitant treatment with psychotropic medications or prescription opioids.
  8. Concomitant use of any one of the following drugs or classes of drugs:

    Reserpine Verapamil theophylline, trimethoprim, cimetidine, haloperidol, benzodiazepines, or antiepileptic drugs (AEDs).

  9. Patients with a known hypersensitivity to aprepitant.
  10. Patients with severe concurrent illnesses such as bronchospastic disease, hyperthyroidism, diabetes mellitus.
  11. Patients with known AIDS or other serious illnesses that may require hospitalization during the study.
  12. Female subjects who are pregnant or lactating, or female subjects of child-bearing potential who are not using acceptable methods of birth control; acceptable methods of birth control include:

    Barrier method (diaphragm or condom) with spermicide Intrauterine progesterone contraceptive system Levonorgesterel implant Medroxyprogesterone acetate contraceptive injection, or Oral contraceptives.

  13. Patients with impaired renal function, as indicated by corrected creatinine clearance below 60 ml/min as determined by the modified Cockcroft equation (CDC, 1986).
  14. An unacceptable liver panel (liver function tests; LFTs) that may be indicative of hepatic dysfunction.
  15. Clinical laboratory tests (e.g., CBC, blood chemistries, urinalysis) outside normal limits, as determined by the study PI.
  16. History of significant heart disease or dysfunction (e.g., an arrhythmia which required medication, Wolff Parkinson -White Syndrome, angina pectoris, documented history of myocardial infarction, heart failure).
  17. Electrocardiography (EKG) indicative of 1st degree heart block, sinus tachycardia, left-axis deviation, non-specific ST or T-wave changes.
  18. History of chest pain associated with cocaine use that prompted a visit to a physician.
  19. Any medical or psychological condition that could jeopardize the subject's safe participation in the trial as determined by the PI.
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01176591
811184
Yes
Jennifer Plebani, University of Pennsylvania
University of Pennsylvania
National Institute on Drug Abuse (NIDA)
Not Provided
University of Pennsylvania
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP